Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2010 - 2026)

Biocryst Pharmaceuticals' Share-based Compensation history runs 17 years deep, the most recent figure standing at $16.0 million for Q1 2026.

• Quarterly Share-based Compensation rose 1086.31% year-over-year to $16.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $99.7 million (up 1426.04% YoY) and the FY2025 annual result came in at $85.1 million, up 1028.94% from the prior year.
• Share-based Compensation was $16.0 million for Q1 2026 at Biocryst Pharmaceuticals, down from $23.8 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $59.1 million in Q3 2025 and bottomed at -$29.4 million in Q4 2022.
• A 5-year average of $11.7 million and a median of $9.7 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2025 — Share-based Compensation plunged 96.46% — and 2026, when it soared 1086.31%.
• Biocryst Pharmaceuticals' Share-based Compensation stood at -$29.4 million in 2022, then jumped by 289.04% to $55.6 million in 2023, then plunged by 94.45% to $3.1 million in 2024, then soared by 671.5% to $23.8 million in 2025, then plunged by 32.64% to $16.0 million in 2026.
• Business Quant data shows BCRX's Share-based Compensation at $16.0 million in Q1 2026, $23.8 million in Q4 2025, and $59.1 million in Q3 2025.